Pancreas Cancer Discussion Page:
An Unmoderated Forum
*
 
Support pancreas research*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER

Pancreas Cancer

Scott-MTA/Lilly-H&N was posted 08/31/2000 04:48 pm by kek
E-mail Address:

Message Text
Scott ... Found this in a search; but it's from 1999 presentation and for Head/Neck cancers. But it's a start. --kek American Society of Gene Therapy - 2nd Annual Meeting 9-13 June 1999, Washington DC, USA Part I Reported by Karen Palmer, Current Drugs Ltd, London, UK Integrating viral vectors (AAV) This session, highlighting one of the major themes of the conference, was chaired by Inder Verma (Salk Institute for Biological Studies, La Jolla, CA, USA). Head and neck cancer LY-231514 The multitargeted antifolate, LY-231514 (MTA; Eli Lilly & Co) was evaluated in a phase II study in patients with metastatic head and neck cancer. The trial enrolled 35 patients, of whom 32 were evaluable. Confirmed partial response (PR) was observed in nine patients, while 14 patients achieved stable disease (SD). Toxicity, mainly leucopenia and neutropenia, was acceptable and further investigation of LY-213514 for this indication is warranted.------

Reply to this message | Return to Main Message List
Responses

*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER


Pancreas Home | Surgical | Medical | Basic Sci | Docs | Registry | FAQ | Appts | Chat

Feedback | Pathology Home | Oncology Center Home | Search
Copyright © 2020 The Johns Hopkins University, Baltimore, Maryland
Last Modified: 11/11/2002 10:50 am